Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DDIT3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DDIT3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DDIT3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/DDIT3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DDIT3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001605515 | Oral cavity | LP | Wnt signaling pathway | 140/4623 | 444/18723 | 5.80e-04 | 5.35e-03 | 140 |
GO:004545418 | Oral cavity | LP | cell redox homeostasis | 18/4623 | 35/18723 | 5.86e-04 | 5.39e-03 | 18 |
GO:019873815 | Oral cavity | LP | cell-cell signaling by wnt | 140/4623 | 446/18723 | 7.12e-04 | 6.38e-03 | 140 |
GO:0051651110 | Oral cavity | LP | maintenance of location in cell | 74/4623 | 214/18723 | 7.18e-04 | 6.41e-03 | 74 |
GO:0051101110 | Oral cavity | LP | regulation of DNA binding | 45/4623 | 118/18723 | 8.04e-04 | 7.06e-03 | 45 |
GO:004352316 | Oral cavity | LP | regulation of neuron apoptotic process | 73/4623 | 212/18723 | 8.87e-04 | 7.64e-03 | 73 |
GO:000698312 | Oral cavity | LP | ER overload response | 9/4623 | 13/18723 | 8.93e-04 | 7.64e-03 | 9 |
GO:005109114 | Oral cavity | LP | positive regulation of DNA-binding transcription factor activity | 86/4623 | 260/18723 | 1.35e-03 | 1.08e-02 | 86 |
GO:0045661 | Oral cavity | LP | regulation of myoblast differentiation | 22/4623 | 51/18723 | 2.96e-03 | 2.03e-02 | 22 |
GO:006082815 | Oral cavity | LP | regulation of canonical Wnt signaling pathway | 82/4623 | 253/18723 | 3.23e-03 | 2.18e-02 | 82 |
GO:003011115 | Oral cavity | LP | regulation of Wnt signaling pathway | 103/4623 | 328/18723 | 3.29e-03 | 2.21e-02 | 103 |
GO:003600318 | Oral cavity | LP | positive regulation of transcription from RNA polymerase II promoter in response to stress | 12/4623 | 24/18723 | 6.44e-03 | 3.78e-02 | 12 |
GO:0043433 | Oral cavity | LP | negative regulation of DNA-binding transcription factor activity | 61/4623 | 185/18723 | 6.68e-03 | 3.89e-02 | 61 |
GO:006007015 | Oral cavity | LP | canonical Wnt signaling pathway | 94/4623 | 303/18723 | 6.97e-03 | 3.96e-02 | 94 |
GO:19904406 | Oral cavity | LP | positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress | 7/4623 | 11/18723 | 7.01e-03 | 3.96e-02 | 7 |
GO:200123318 | Prostate | BPH | regulation of apoptotic signaling pathway | 134/3107 | 356/18723 | 5.06e-22 | 7.84e-19 | 134 |
GO:009719318 | Prostate | BPH | intrinsic apoptotic signaling pathway | 110/3107 | 288/18723 | 7.36e-19 | 2.85e-16 | 110 |
GO:007259416 | Prostate | BPH | establishment of protein localization to organelle | 142/3107 | 422/18723 | 4.01e-18 | 1.31e-15 | 142 |
GO:001049818 | Prostate | BPH | proteasomal protein catabolic process | 153/3107 | 490/18723 | 4.13e-16 | 7.51e-14 | 153 |
GO:003497618 | Prostate | BPH | response to endoplasmic reticulum stress | 95/3107 | 256/18723 | 1.54e-15 | 2.52e-13 | 95 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501239 | Esophagus | HGIN | Parkinson disease | 124/1383 | 266/8465 | 5.95e-32 | 9.70e-30 | 7.70e-30 | 124 |
hsa0502030 | Esophagus | HGIN | Prion disease | 117/1383 | 273/8465 | 4.15e-26 | 3.38e-24 | 2.69e-24 | 117 |
hsa0501430 | Esophagus | HGIN | Amyotrophic lateral sclerosis | 140/1383 | 364/8465 | 2.13e-25 | 1.16e-23 | 9.19e-24 | 140 |
hsa0502230 | Esophagus | HGIN | Pathways of neurodegeneration - multiple diseases | 153/1383 | 476/8465 | 1.22e-18 | 4.41e-17 | 3.50e-17 | 153 |
hsa0501030 | Esophagus | HGIN | Alzheimer disease | 130/1383 | 384/8465 | 5.26e-18 | 1.71e-16 | 1.36e-16 | 130 |
hsa0493230 | Esophagus | HGIN | Non-alcoholic fatty liver disease | 66/1383 | 155/8465 | 5.21e-15 | 1.21e-13 | 9.64e-14 | 66 |
hsa0414139 | Esophagus | HGIN | Protein processing in endoplasmic reticulum | 67/1383 | 174/8465 | 1.06e-12 | 2.16e-11 | 1.72e-11 | 67 |
hsa0421020 | Esophagus | HGIN | Apoptosis | 36/1383 | 136/8465 | 1.67e-03 | 1.52e-02 | 1.20e-02 | 36 |
hsa0541739 | Esophagus | HGIN | Lipid and atherosclerosis | 51/1383 | 215/8465 | 2.95e-03 | 2.41e-02 | 1.91e-02 | 51 |
hsa05012114 | Esophagus | HGIN | Parkinson disease | 124/1383 | 266/8465 | 5.95e-32 | 9.70e-30 | 7.70e-30 | 124 |
hsa05020113 | Esophagus | HGIN | Prion disease | 117/1383 | 273/8465 | 4.15e-26 | 3.38e-24 | 2.69e-24 | 117 |
hsa05014113 | Esophagus | HGIN | Amyotrophic lateral sclerosis | 140/1383 | 364/8465 | 2.13e-25 | 1.16e-23 | 9.19e-24 | 140 |
hsa05022113 | Esophagus | HGIN | Pathways of neurodegeneration - multiple diseases | 153/1383 | 476/8465 | 1.22e-18 | 4.41e-17 | 3.50e-17 | 153 |
hsa05010113 | Esophagus | HGIN | Alzheimer disease | 130/1383 | 384/8465 | 5.26e-18 | 1.71e-16 | 1.36e-16 | 130 |
hsa04932113 | Esophagus | HGIN | Non-alcoholic fatty liver disease | 66/1383 | 155/8465 | 5.21e-15 | 1.21e-13 | 9.64e-14 | 66 |
hsa04141114 | Esophagus | HGIN | Protein processing in endoplasmic reticulum | 67/1383 | 174/8465 | 1.06e-12 | 2.16e-11 | 1.72e-11 | 67 |
hsa04210110 | Esophagus | HGIN | Apoptosis | 36/1383 | 136/8465 | 1.67e-03 | 1.52e-02 | 1.20e-02 | 36 |
hsa05417114 | Esophagus | HGIN | Lipid and atherosclerosis | 51/1383 | 215/8465 | 2.95e-03 | 2.41e-02 | 1.91e-02 | 51 |
hsa04141211 | Esophagus | ESCC | Protein processing in endoplasmic reticulum | 147/4205 | 174/8465 | 3.29e-22 | 1.10e-19 | 5.64e-20 | 147 |
hsa05014210 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
DDIT3 | CD8TRM | Cervix | CC | AKR1A1,DNAJB1,TNFAIP6, etc. | 1.55e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Cervix/Str/TF_CC/regulons_activity_in_dotplot.png) |
DDIT3 | CD4TN | Endometrium | EEC | SNHG12,C6orf48,SLC3A2, etc. | 9.94e-02 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Endometrium/Str/TF_EEC/regulons_activity_in_dotplot.png) |
DDIT3 | CD8TRM | Esophagus | ESCC | TIAF1,FAM20B,DNAJB1, etc. | 4.71e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Esophagus/Str/TF_ESCC/regulons_activity_in_dotplot.png) |
DDIT3 | TFH | Lung | MIAC | HSPE1,HSPD1,HSP90AA1, etc. | 2.26e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Lung/Str/TF_MIAC/regulons_activity_in_dotplot.png) |
DDIT3 | TFC | Thyroid | Healthy | ID3,SNHG5,LIMCH1, etc. | 2.75e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Thyroid/Str/TF_Healthy/regulons_activity_in_dotplot.png) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1649 | DDIT3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR | | FENRETINIDE | FENRETINIDE | 12234979,17273769 |
1649 | DDIT3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR | | PROTEIN SYNTHESIS INHIBITOR | | 1735464 |
1649 | DDIT3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR | | TAXOL | PACLITAXEL | 8554977 |
1649 | DDIT3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR | | SURAMIN | SURAMIN | 9586958 |
1649 | DDIT3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR | | DICLOFENAC | DICLOFENAC | 15131590 |
1649 | DDIT3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR | | PHOTOSENSITIZER | | 15611953 |
1649 | DDIT3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR | | QUINONE | | 8794898 |
1649 | DDIT3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR | | TAXOTERE | TAXOTERE | 10470115 |
1649 | DDIT3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR | | CISPLATIN | CISPLATIN | 10071988,8554977 |
1649 | DDIT3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR | | STAUROSPORINE | STAUROSPORINE | 17167033 |